News
Biosimilars - Curaxys Has Three Biotechnological
Platforms For The Biosimilars / Biogenerics Production
By
Curaxys - 26
November 2009
The biosimilars production has been
incorporate to the new technological platforms of Curaxys in order to get
more competitive processes and products. Curaxys has been pioneer in the use
of those technologies, mainly in the baculovirus expression system.
(1888PressRelease)
The technological platforms are based on mammalian cell culture, insect
cell culture using the baculovirus expression system, and plant cells.
Dr. Esteban, CEO of Curaxys said that the mentioned agreements will
provide a very competitive biotechnological process for biosimilars
production.
The company is very attractive due to the technology and the importance
of the products. Curaxys will invest 40 million € to built up a brand
new research center, in order to carry out the research, development and
production operations.
Dr. Esteban said that it is relevant to mention that the facilities of
the biopharmaceutical pilot plant will be working in a GMP environment,
in order to produce the material to be used in clinical research.
Related to the industrial pharmaceuticals activities, Curaxys will
manage an injectable pharmaceurical plant for oncology drugs with a
capacity for ten million units.
Dr Esteban said that Curaxys has been presented to the Regional Spanish
Health Authorities and the Regional R&D Agency and it has been evaluated
excellent and both parties are elaborating the protocols and agreement
of collaborations.
The activities in the field of clinical research will be planned with
the Universities of Cadiz and they will be designed into the University
Hospital of the Cadiz Province. The agreements will be signed in short
term.